Shang Hai Di SAi Nuo Sheng Wu Yi Yao You Xian Gong Si

Primary objective: To investigate the in vivo pharmacokinetic characteristics of Letermovir Tablets (Specification: 240 mg) (produced by Jiangxi Desano Pharmaceutical Group Co., Ltd.) and Premin® (Specification: 240 mg) (licensed by Merck Sharp & Dohme B.V.) in healthy subjects after a single oral administration under fasting/postprandial conditions, and to evaluate the bioequivalence of the two preparations. Secondary objective: To observe the safety of the test preparation and reference preparation of Letermovir Tablets (Specification: 240 mg) in healthy subjects after a single oral administration.

Main purpose: To investigate the in vivo pharmacokinetic characteristics of the test preparation (Dolutegravir Lamivudine Tenofovir Tablets (Specifications: 50mg/300mg/300mg)) produced by Shanghai Desano Pharmaceutical Group Co., Ltd. and the reference preparation (Dolutegravir Sodium Tablets (Tivicay®, Specification: 50mg) + Lamivudine Tablets (EPIVIR®, Specification: 300mg) + Tenofovir Disoproxil Fumarate Tablets (Viread®, Specification: 300mg)) in Chinese healthy subjects after single oral administration under fasting/postprandial conditions, and to evaluate the bioequivalence of the test preparation and the reference preparation. Secondary objective: To evaluate the safety of a single oral dose of the test formulation (dolutegravir lamivudine and tenofovir disoproxil fumarate tablets (specifications: 50 mg/300 mg/300 mg)) produced by Shanghai Desano Pharmaceutical Group Co., Ltd. and the combined administration of the reference formulation (dolutegravir sodium tablets (Tivica®, specification: 50 mg) + lamivudine tablets (EPIVIR®, specification: 300 mg) + tenofovir disoproxil fumarate tablets (Viread®, specification: 300 mg)) in healthy Chinese subjects.

Primary objective: To investigate the in vivo pharmacokinetic characteristics of lamivudine-dolutegravir tablets (specifications: lamivudine 300 mg/dolutegravir sodium 50 mg (in terms of dolutegravir)) produced by Shanghai Desano Pharmaceutical Group Co., Ltd. and lamivudine-dolutegravir tablets (Dovito®, specifications: lamivudine 300 mg/dolutegravir sodium 50 mg (in terms of dolutegravir)) produced by licensee Viiv Healthcare B.V. in healthy Chinese subjects after single oral administration under fasting/postprandial conditions, and to evaluate the bioequivalence of the two preparations. Secondary objective: To evaluate the safety of the test preparation and reference preparation of lamivudine-dolutegravir tablets in healthy Chinese subjects after single oral administration.